Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Use of total lymphocyte count for monitoring response to antiretroviral therapy.

Schreibman T, Friedland G.

Clin Infect Dis. 2004 Jan 15;38(2):257-62.

2.
3.

Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings.

Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S, Carpenter CC, Mayer KH, Flanigan TP.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):567-75.

PMID:
15097299
4.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida..

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
6.

Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy.

Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C, DeHovitz J, Delapenha R, Hoover DR.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):383-92.

PMID:
15097155
7.

API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.

Gupta SB, Pujari SN, Joshi SR, Patel AK; AIDS Society of India Guidelines Development Committee..

J Assoc Physicians India. 2006 Jan;54:57-74. Review.

PMID:
16649742
8.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA.; Plan Nacional sobre el Sida..

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
9.

Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy.

Gupta A, Gupte N, Bhosale R, Kakrani A, Kulkarni V, Nayak U, Thakar M, Sastry J, Bollinger RC; Byramji Jeejeebhoy Medical College-Johns Hopkins University Study Group..

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):338-42.

PMID:
17846559
10.
11.

Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression.

Nnoruka EN, Chukwuka JC, Anisuiba B.

Int J Dermatol. 2007 Oct;46 Suppl 2:14-8.

PMID:
17958624
12.

Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?

Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, Saag MS.

Clin Infect Dis. 2007 Jan 1;44(1):135-8.

13.

Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries.

Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, Thyagarajan SP, Solomon S.

J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):378-83.

PMID:
12447007
14.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group.; Italian Cohort Naive for Antiretrovirals Study Group..

Clin Infect Dis. 2005 Jun 15;40(12):e101-9.

15.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
16.

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.

Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.

AIDS. 2006 May 12;20(8):1171-9.

PMID:
16691069
17.

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.

Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A.

AIDS. 2007 Jan 30;21(3):351-9.

PMID:
17255742
18.

Correlation analysis on total lymphocyte count and CD4 count in HIV-infected patients: a retrospective evaluation.

Wang Y, Liang S, Yu E, Guo J, Li Z, Wang Z, Du Y.

J Huazhong Univ Sci Technolog Med Sci. 2011 Oct;31(5):712-6. doi: 10.1007/s11596-011-0588-8.

PMID:
22038367
19.

Correlation analysis on total lymphocyte count and CD4 count of HIV-infected patients.

Liu FR, Guo F, Ye JJ, Xiong CF, Zhou PL, Yin JG, Ye LX.

Int J Clin Pract. 2008 Jun;62(6):955-60.

PMID:
17983435
20.

The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.

Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.

Pediatrics. 2005 Apr;115(4):e488-94.

PMID:
15772172
Items per page

Supplemental Content

Support Center